Overview of omega-3 fatty acid therapies

P and T

Volumn 38, Issue 11, 2013, Pages 681-691

  Chris Bradberry, J ^a   Hilleman, Daniel E ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

Docosahexaenoic acid; Dyslipidemias; Eicosapentaenoic acid; Omega 3 fatty acids; Triglycerides

Indexed keywords

ALPHA TOCOPHEROL; CAPRE; COD LIVER OIL; DOCOSAHEXAENOIC ACID; EPANOVA; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; KRILL OIL; LAROPIPRANT PLUS NICOTINIC ACID; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; SUPERBA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; ERUCTATION; FLATULENCE; FLUSHING; GOUT; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; META ANALYSIS (TOPIC); MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT ATTITUDE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TASTE DISORDER; TREATMENT OUTCOME;

EID: 84887853471     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Nettleton JA. Omega-3 Fatty Acids and Health. New York: Springer (formerly Chapman & Hall); 1995.
2. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343S-348S.
3. Koski RR. Omega-3-acid ethyl esters (Lovaza) for severe hypertriglyceridemia. P&T 2008;33:271-281, 303.
4. Surette ME. The science behind dietary omega-3 fatty acids. Can Med Assoc J 2008;178:177-180.
5. Tur JA, Bibiloni MM, Sureda A, Pons A. Dietary sources of omega 3 fatty acids: Public health risks and benefits. Br J Nutr 2012;107(Suppl 2):S23-S52.
6. Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: New recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003;23:151-152
7. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: A systematic review. Br J Nutr 2012;107(Suppl 2):S201-S213.
8. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-594.
9. Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO Jr, ed. The Johns Hopkins Textbook of Dyslipidemia. Philadelphia: Lippincott Williams & Wilkins/ Wolters Kluwer Health; 2010:245-257.
10. FDA announces qualified health claims for omega-3 fatty acids. Available at: www.fda.gov/SiteIndex/ucm108351.htm. Accessed June 27, 2013.
11. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455.
12. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-1098.
13. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-2026.
14. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-2159.
15. Kromhout D, Geleijnse JM, de GJ, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011;34:2515-2520.
16. ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-318.
17. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega-3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. BMJ 2010;341:c6273.
18. Blacher J, Czernichow S, Paillard F, et al. Cardiovascular effects of B-vitamins and/or n-3 fatty acids: The Su.Fol.Om3 trial. Int J Cardiol 2013;167:508-513.
19. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-1230.
20. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. JAMA 2012;308:1024-1033.
21. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes Vasc Dis Res 2008;5:319-335.
22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), Final Report. Circulation 2002;106:3143-3421.
23. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among U.S. adults. Arch Intern Med 2009;169:572-578.
24. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011;123:2292-2333.
25. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
26. Kones R. Primary prevention of coronary heart disease: Integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Design Devel Ther 2011;5:325-380.
27. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: A collaborative approach. Circulation 2005;112:3184-3209.
28. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-2989.
29. Harris WS. n-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 1997;65:1645S-1654S.
30. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757.
31. Nordoy A, Barstad L, Connor WE, Hatcher L. Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans. Am J Clin Nutr 1991;53:1185-1190.
32. Krokan HE, Bjerve KS, Mork E. The enteral bioavailability of eicosapentaenoic acid and docosahexaenoic acid is as good from ethyl esters as from glyceryl esters in spite of lower hydrolytic rates by pancreatic lipase in vitro. Biochim Biophys Acta 1993;1168:59-67.
33. Hansen JB, Olsen JO, Wilsgard L, et al. Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis, and platelet function in normolipaemic men. Eur J Clin Nutr 1993;47:497-507.
34. Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review. Atherosclerosis 2006;189:19-30.
35. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999;143:285-297.
36. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Exp Rev Cardiovasc Ther 2008;6:391-409.
37. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-1367.
38. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. J Clin Lipidol 2012;6:5-18.
39. Egert S, Kannenberg F, Somoza V, et al. Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 2009;139:861-868.
40. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997;66:649-659.
41. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76:1007-1015.
42. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71:1085-1094.
43. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis. Curr Atheroscler Rep 2011;13:474-483.
44. Tatsuno I, Saito Y, Kudou K, Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The Omega-3 fatty acids Randomized Double-blind (ORD) study. J Clin Lipidol 2013;7:199-207.
45. Nestel P, Shige H, Pomeroy S, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002;76:326-330.
46. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177-2184.
47. Kurabayashi T, Okada M, Tanaka K; The Niigata Epadel Study Group. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. Obstet Gynecol 2000;96:521-528.
48. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care 2007;30:144-146.
49. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multicenter, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-690.
50. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statintreated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984-992.
51. Brunton S, Collins N. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr Med Res Opin 2007;23:1139-1145.
52. Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: A legislative and regulatory perspective. J Am Coll Nutr 2008;27:659-666.
53. FDA. Regulatory information: Dietary supplement health and education act of 1994. Available at: www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm. Accessed June 27, 2013.
54. Zargar A, Ito MK. Long chain omega-3 dietary supplements: A review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord 2011;9:255-271.
55. Omega-3 oil: Fish or pills? Consumer Rep 2003;30-32.
56. Fish oil and omega-3 fatty acid supplements (EPA and DHA from fish, algae, and krill). Consumer Lab Available at: https://www.consumerlab.com/reviews/fish_oil_supplements_review/omega3/. Accessed June 27, 2013.
57. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C-43C.
58. The name Omacor (Omega-3-acid ethyl esters) will be Lovaza. Reliant Pharmaceuticals, Inc. Available at: www.ncbop.org/PDF/OmacorBecomesLovazaJuly2007.pdf. Accessed June 27, 2013.
59. Lovaza, prescribing information. Research Triangle Park, N.C.: GlaxoSmithKline; 2012.
60. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-391.
61. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
62. Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3 ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 2009;3:332-340.
63. Vascepa, prescribing information. Bedminster, N.J.: Amarin Pharma, Inc.; 2012.
64. Davidson MH, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol 2011;22:437-444.
65. Epanova overview. Omthera Pharmaceuticals. Available at: www.omthera.com/epanova_overview.html. Accessed June 27, 2013.
66. Davidson MH, Johnson J, Rooney MW, et al. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation) study. J Clin Lipidol 2012;6:573-584.
67. Kastelein JJ, Maki KC, Susekov A, et al. Dose reponse of a novel free-fatty acid formulation of omega-3 for the management of dyslipidemia in patients with severe hypertriglyceridemia: EpanoVa fOr Lowering Very High TriglycErides (the EVOLVE trial) (Abstract 16374). Circulation 2012;126.
68. Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther 2013;35(9): 1400-1411.e3.
69. The effect of multiple doses of Epanova® on the multiple-dose pharmacokinetics of simvastatin in healthy normal subjects. Available at: www.clinicaltrials.gov/ct2/show/record/NCT01486433?term=NCT01486433&rank=1. Accessed June 27, 2013.
70. Krill oil. Monograph. Altern Med Rev 2010;15:84-86.
71. Bunea R, El FK, Deutsch L. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev 2004;9:420-428.
72. Neptune Krill Oil specifications. Neptune Technologies & Bioressources. Available at: www.neptunebiotech.com/sites/default/files/Neptune_Krill_Oil_Specifications_Sheet.pdf. Accessed June 27, 2013.
73. Maki KC, Reeves MS, Farmer M, et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res 2009;29:609-615.
74. Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA in healthy volunteers. Lipids 2011;46:37-46.
75. Harris WS, von SC. The Omega-3 Index: A new risk factor for death from coronary heart disease? Prev Med 2004;39:212-220.
76. TRIal For Efficacy of CaPre on hyperTriglyceridemiA (TRIFECTA). Available at: http://clinicaltrials.gov/ct2/show/NCT01455 844?term=%28TRIFECTA%29.&rank=1. Accessed June 27, 2013.
77. Schmier JK, Rachman NJ, Halpern MT. The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events. Manag Care 2006;15:43-50.
78. Cowie MR, Cure S, Bianic F, et al. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: Results of Markov modelling in a U.K. setting. Eur J Heart Fail 2011;13:681-689.
79. Franzosi MG, Brunetti M, Marchioli R, et al. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: Results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001;19:411-420.
80. Christian JB, Arondekar B, Buysman E, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol 2012;6:450-461.
81. Nichols GA, Arondekar B, Garrison LP Jr. Patient characteristics and medical care costs associated with hypertriglyceridemia. Am J Cardiol 2011;107:225-229.
82. Nichols GA, Arondekar B, Jacobson TA. Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. J Clin Lipidol 2012;6:443-449.
83. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
84. Merck announces HPS2-THRIVE study of Tredaptive™ (extendedrelease niacin/laropiprant) did not achieve primary endpoint, December 20, 2012. Available at: www.mercknewsroom.com. Accessed June 27, 2013.
85. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: Trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291.
86. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
87. A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). Available at: http://clinicaltrials.gov/show/ NCT01492361. Accessed June 27, 2013